Go to the list of all blogs
published in Blogs
Jul 14, 2026
The Baldwin Insurance Group (BWIN) Surges +50.7% on Strategic Review News

The Baldwin Insurance Group (BWIN) Surges +50.7% on Strategic Review News

Key Takeaways

  • The Baldwin Insurance Group (BWIN) surged approximately 50.7% over the last 30 days, driven by reports the company is exploring strategic options including a potential take-private transaction.
  • JPMorgan upgraded BWIN to Overweight from Neutral and raised its price target to $30, reinforcing bullish sentiment around the stock.
  • Multiple analyst firms — including Keefe Bruyette & Woods, TD Cowen, and Morgan Stanley — issued favorable ratings or raised price targets, citing improving fundamentals and attractive valuation.
  • Strong Q1 2026 results, featuring 29% year-over-year revenue growth and rapid synergy capture from the CAC Group acquisition, provided fundamental support for the rally.
  • The stock's quarterly performance reflects a broader recovery from oversold levels, with shares up approximately 13.7% over the last quarter despite earlier weakness.

Company Overview and Market Position

The Baldwin Insurance Group, Inc. — operating under the brand name The Baldwin Group — is an independent insurance distribution firm headquartered in Tampa, Florida. Formerly known as BRP Group, Inc., the company rebranded in May 2024 and trades on the NASDAQ under the ticker BWIN. The firm delivers tailored insurance and risk management solutions across three operating segments: Insurance Advisory Solutions (commercial risk management, employee benefits, and private risk management for businesses and high-net-worth individuals), Underwriting, Capacity & Technology Solutions (including its MGA platform MSI, reinsurance brokerage Juniper Re, and captive management), and Mainstreet Insurance Solutions (personal, commercial, and life and health products distributed through community-based channels). Representing more than three million clients across the United States, Baldwin has built a scalable, technology-enabled platform that combines organic growth with strategic acquisitions — most notably the January 2026 merger with CAC Group, a specialty and middle-market brokerage that significantly expanded the company's capabilities in property and casualty, personal lines, and employee benefits.

Stock Price Performance: Last 30 Days vs. Quarter

BWIN shares delivered a dramatic rally over the last 30 days, climbing approximately 50.7% from a closing price of $18.13 on June 12 to $27.32 as of July 13. The move was punctuated by an explosive single-day surge on June 18, when shares jumped roughly 16.8% on volume exceeding 6.1 million shares — more than three times the daily average — following news that the company had retained advisers to evaluate strategic alternatives including a potential take-private transaction. The rally continued through the end of June and into July, supported by a cascade of analyst upgrades and rising institutional interest. Over the last quarter, BWIN has gained approximately 13.7%, moving from $24.03 in mid-April to the current level. The quarterly trend tells a story of early spring weakness — shares fell as low as $18.13 by mid-June — followed by the sharp late-quarter recovery fueled by strategic speculation and improving sentiment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Drove the 30-Day Surge

The primary catalyst for BWIN's 30-day surge was the June 18 disclosure that the insurance brokerage is exploring strategic options, including a potential take-private deal backed by private equity. This immediately reframed the investment narrative, as insurance brokerages generate recurring, contractual commission revenue and operate with low capital requirements — precisely the profile that attracts private equity buyers who can deploy leverage in ways public markets constrain. JPMorgan analyst Pablo Singzon followed the news on June 22 with an upgrade to Overweight from Neutral, raising the price target to $28 from $25 and describing a take-private as a "credible enough outcome" that could crystallize value. JPMorgan subsequently raised its target again to $30 on July 13. The analyst wave was broad: Morgan Stanley set a $28 target, BMO Capital raised its target to $25, and Keefe Bruyette & Woods lifted its target to $31 with an Outperform rating on July 8. Additionally, Artisan Partners disclosed a new position in early June, voicing confidence in Baldwin's business model and its resilience to AI-driven disruption. The company's Q1 2026 results — $532.2 million in revenue (up 29% year-over-year), adjusted EBITDA of $137.2 million (up 21%), and rapid synergy realization from the CAC Group acquisition — reinforced the fundamental case even as the strategic review captured headlines.

Quarterly Performance Drivers

BWIN's quarterly performance was shaped by two distinct phases. Through April and May, the stock trended lower amid concerns about margin compression, elevated leverage of approximately 4.3x net debt to EBITDA, and modest organic revenue growth of roughly 2% in Q1 2026 — excluding the contribution from newly acquired partnerships. A significant insider sale by major shareholder Elizabeth Krystyn of 130,018 shares at $21.20 on May 7 added to near-term selling pressure. Sentiment began to shift in early June following TD Cowen's reiterated Buy rating and $37 price target, which named BWIN its 2026 small- to mid-cap top pick and highlighted the stock's discounted valuation at 7.2 times 2027 estimated earnings versus a peer average of roughly 14 times. The William Blair Growth Stock Conference presentation on June 3 also provided management an opportunity to articulate the company's growth roadmap. The take-private exploration news in mid-June then served as the decisive turning point, transforming the quarterly performance from negative territory into positive gains and setting the stage for sustained upward momentum into July.

Using Tickeron’s Trending AI Robots for Market Context

In dynamic markets, identifying timely opportunities can be challenging — which is where Tickeron's Trending AI Robots page offers a data-driven resource that I find useful in my own workflow. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across various strategies, timeframes, and market conditions. However, only the top-performing and most relevant bots rise to the Trending section — a curated display designed to highlight strategies that are currently resonating with real-time market dynamics. These bots employ diverse methodologies, from swing trading and trend-following to breakout and pattern-recognition approaches, each with distinct risk and performance profiles. For traders and investors seeking systematic, algorithm-driven insights, exploring the Trending AI Robots page can provide a practical entry point into AI-assisted decision-making. I have used this resource to cross-check momentum signals around names like BWIN when strategic developments emerge. Visit the Trending AI Robots page to discover which strategies are capturing attention right now.

BWIN Stock Forecast Drivers: What Investors Should Watch Next

The most immediate event on BWIN's calendar is the company's second-quarter 2026 earnings report, scheduled for July 30, 2026. Analysts will be closely watching organic revenue growth trends, margin trajectory, progress on the CAC Group integration — including cross-sell execution and further synergy realization — and any updates on the strategic review process. Management previously guided for Q2 revenue of $485 million to $490 million and mid-single-digit organic growth, with acceleration expected in the second half of the year. Beyond earnings, investors should monitor developments around the potential take-private transaction, as any formal offer or termination of the strategic review would likely drive significant price action. Macroeconomic factors — including interest rate expectations, commercial insurance pricing cycles, and credit market conditions — will also influence both Baldwin's operating environment and the feasibility of any leveraged buyout. The company's $250 million share repurchase authorization, with approximately $203 million remaining, represents an additional source of potential demand for shares, though buybacks may be deprioritized if a take-private process advances.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: BWIN

BWIN sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for BWIN moved above the 200-day moving average on July 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on BWIN as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BWIN just turned positive on August 03, 2026. Looking at past instances where BWIN's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BWIN advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 212 cases where BWIN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BWIN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BWIN broke above its upper Bollinger Band on August 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BWIN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.396) is normal, around the industry mean (8.009). P/E Ratio (0.000) is within average values for comparable stocks, (36.010). BWIN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.729). BWIN's Dividend Yield (0.000) is considerably lower than the industry average of (0.014). P/S Ratio (1.223) is also within normal values, averaging (3.220).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BWIN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are eHealth (NASDAQ:EHTH).

Industry description

Insurance brokers sell, solicit, or negotiate insurance for compensation. General insurance brokers mostly cater to insurances on car, house etc. (versus life). Brokers are also often instrumental in helping small employers find health insurance, particularly in more competitive markets. Additionally, brokers may also provide risk assessments, insurance consulting services, insurance-related regulatory and legislative update services. Some of the major names in this industry include Marsh & McLennan Companies, Inc., Aon plc and Verisk Analytics Inc.

Market Cap

The average market capitalization across the Insurance Brokers/Services Industry is 15.96B. The market cap for tickers in the group ranges from 377.24K to 90.13B. MRSH holds the highest valuation in this group at 90.13B. The lowest valued company is TIRX at 377.24K.

High and low price notable news

The average weekly price growth across all stocks in the Insurance Brokers/Services Industry was 20%. For the same Industry, the average monthly price growth was 27%, and the average quarterly price growth was 40%. LIFE experienced the highest price growth at 21%, while ZBAO experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Insurance Brokers/Services Industry was 31%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 70
P/E Growth Rating: 71
Price Growth Rating: 55
SMR Rating: 73
Profit Risk Rating: 83
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
BWIN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry InsuranceBrokersServices

Profile
Details
Interact to see
Advertisement
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.